Short Interest in Theratechnologies Inc. (NASDAQ:THTX) Grows By 38.8%

Theratechnologies Inc. (NASDAQ:THTX) saw a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 25,400 shares, an increase of 38.8% from the July 15th total of 18,300 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 37,200 shares, the short-interest ratio is currently 0.7 days.

Theratechnologies Stock Performance

Shares of THTX stock traded down $0.02 on Friday, hitting $1.36. The company had a trading volume of 14,706 shares, compared to its average volume of 48,358. The stock’s 50-day moving average is $1.39 and its two-hundred day moving average is $1.40. Theratechnologies has a twelve month low of $0.88 and a twelve month high of $3.29. The firm has a market cap of $62.30 million, a P/E ratio of -7.13 and a beta of 1.43.

Theratechnologies (NASDAQ:THTX) last released its earnings results on Wednesday, July 10th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.04. The business had revenue of $22.02 million for the quarter. During the same period in the prior year, the company earned ($0.40) earnings per share. Equities research analysts predict that Theratechnologies will post -0.02 EPS for the current year.

Institutional Trading of Theratechnologies

Hedge funds have recently made changes to their positions in the company. AIGH Capital Management LLC boosted its holdings in Theratechnologies by 362.9% in the 4th quarter. AIGH Capital Management LLC now owns 3,719,302 shares of the company’s stock valued at $6,025,000 after purchasing an additional 2,915,906 shares during the period. Bare Financial Services Inc bought a new position in Theratechnologies in the 4th quarter valued at $39,000. Worth Venture Partners LLC boosted its holdings in Theratechnologies by 362.5% in the 4th quarter. Worth Venture Partners LLC now owns 906,557 shares of the company’s stock valued at $1,469,000 after purchasing an additional 710,551 shares during the period. National Bank of Canada FI boosted its holdings in Theratechnologies by 65.4% in the 4th quarter. National Bank of Canada FI now owns 113,378 shares of the company’s stock valued at $191,000 after purchasing an additional 44,825 shares during the period. Finally, Wealthspire Advisors LLC bought a new position in Theratechnologies in the 4th quarter valued at $83,000.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.